Literature DB >> 21704889

Efficacy of sublingual immunotherapy with house dust mite extract in polyallergen sensitized patients with allergic rhinitis.

Ji-Eun Lee1, Yoon-Seok Choi, Min-Su Kim, Doo Hee Han, Chae-Seo Rhee, Chul Hee Lee, Dong-Young Kim.   

Abstract

BACKGROUND: It is suggested that polysensitized patients might not benefit from specific allergic rhinitis immunotherapy as much as monosensitized patients, although further research on this subject is needed.
OBJECTIVE: To compare the efficacy of sublingual immunotherapy (SLIT) with standardized house dust mite extract in monosensitized and polysensitized patients with allergic rhinitis.
METHODS: Patients who were sensitized to house dust mites and treated with SLIT for house dust mites for at least 1 year between November 2007 and March 2010 were studied. The monoallergen sensitized group was defined as patients who were sensitized to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae (n = 70). The polyallergen sensitized group was defined as patients who were simultaneously sensitized to house dust mites and other allergens (n = 64). A standardized extract of house dust mites was used for immunotherapy. Antiallergic medication and the total nasal symptom score (TNSS), including rhinorrhea, sneezing, nasal obstruction, and itchy nose, were evaluated before and 1 year after SLIT.
RESULTS: This study enrolled 134 patients. The TNSS improved significantly after SLIT in both groups, whereas the change in the TNSS did not differ significantly between the groups. The antiallergic medication scores also decreased significantly in both groups, but there was no significant difference between the groups.
CONCLUSIONS: In polysensitized allergic rhinitis patients, SLIT for D pteronyssinus and/or D farinae produced improvements in both nasal symptoms and rescue medication scores comparable to those in monosensitized patients, regardless of other positive allergens. SLIT for D pteronyssinus and/or D farinae should be considered in polysensitized allergic rhinitis patients.
Copyright © 2011 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704889     DOI: 10.1016/j.anai.2011.03.012

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  8 in total

Review 1.  Sublingual immunotherapy for pediatric allergic rhinitis: The clinical evidence.

Authors:  Dimitri Poddighe; Amelia Licari; Silvia Caimmi; Gian Luigi Marseglia
Journal:  World J Clin Pediatr       Date:  2016-02-08

2.  Environmental assessment and exposure control of dust mites: a practice parameter.

Authors:  Jay Portnoy; Jeffrey D Miller; P Brock Williams; Ginger L Chew; J David Miller; Fares Zaitoun; Wanda Phipatanakul; Kevin Kennedy; Charles Barnes; Carl Grimes; Désirée Larenas-Linnemann; James Sublett; David Bernstein; Joann Blessing-Moore; David Khan; David Lang; Richard Nicklas; John Oppenheimer; Christopher Randolph; Diane Schuller; Sheldon Spector; Stephen A Tilles; Dana Wallace
Journal:  Ann Allergy Asthma Immunol       Date:  2013-12       Impact factor: 6.347

Review 3.  The Role of Allergen-Specific Immunotherapy in ENT Diseases: A Systematic Review.

Authors:  Elena Cantone; Stefania Gallo; Sara Torretta; Aikaterini Detoraki; Carlo Cavaliere; Claudio Di Nola; Luca Spirito; Tiziana Di Cesare; Stefano Settimi; Daniela Furno; Lorenzo Pignataro; Eugenio De Corso
Journal:  J Pers Med       Date:  2022-06-09

4.  Sublingual immunotherapy: World Allergy Organization position paper 2013 update.

Authors:  Giorgio Walter Canonica; Linda Cox; Ruby Pawankar; Carlos E Baena-Cagnani; Michael Blaiss; Sergio Bonini; Jean Bousquet; Moises Calderón; Enrico Compalati; Stephen R Durham; Roy Gerth van Wijk; Désirée Larenas-Linnemann; Harold Nelson; Giovanni Passalacqua; Oliver Pfaar; Nelson Rosário; Dermot Ryan; Lanny Rosenwasser; Peter Schmid-Grendelmeier; Gianenrico Senna; Erkka Valovirta; Hugo Van Bever; Pakit Vichyanond; Ulrich Wahn; Osman Yusuf
Journal:  World Allergy Organ J       Date:  2014-03-28       Impact factor: 4.084

5.  The efficacy assessment of a self-administered immunotherapy protocol.

Authors:  Frederick M Schaffer; Larry M Garner; Myla Ebeling; Jeffrey M Adelglass; Thomas C Hulsey; Andrew R Naples
Journal:  Int Forum Allergy Rhinol       Date:  2015-10-14       Impact factor: 3.858

Review 6.  Presence of positive skin prick tests to inhalant allergens and markers of T2 inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review.

Authors:  Melanie Mitsui Wong; Paul Kevin Keith
Journal:  Allergy Asthma Clin Immunol       Date:  2020-08-04       Impact factor: 3.406

7.  Current specific immunotherapy for allergic rhinitis: perspectives from otorhinolaryngologists.

Authors:  Chae-Seo Rhee
Journal:  Allergy Asthma Immunol Res       Date:  2014-06-19       Impact factor: 5.764

8.  Sublingual grass allergen specific immunotherapy: a retrospective study of clinical outcome and discontinuation.

Authors:  Christer Janson; Fredrik Sundbom; Peter Arvidsson; Mary Kämpe
Journal:  Clin Mol Allergy       Date:  2018-06-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.